keyboard_arrow_downkeyboard_arrow_upPRODUCTS HLA PEPTIDE DATABASE
BLOG
TECHNOLOGY
ABOUT
Alithea Bio combines leading immunopeptidomics methods, highly sensitive mass spectrometry and machine learning to provide world leading results in the characterization of HLA peptides from cell lines, tissues and blood.
Our immunopeptidomics data facilitates the discovery of novel HLA peptide targets, the validation of potential targets and the prediction and verification of off-targets.
Request HLA database demo
Fine-tuning immunotherapy treatment by deciphering HLA-peptide T cell interactions
THE PRECISION IMMUNOTHERAPY COMPANY
keyboard_arrow_left
Go to database login page
Request a demo
Alithea’s HLA Peptide Database
Alithea's web-accessible HLA peptide database consists of 4100+ high quality HLA peptidomics samples from healthy organs, cancer cell lines and tumor tissues.
It features an easy user interface to search in the up to 10'000 target candidates, perform quantification of the presentation of epitopes in healthy and tumor tissues and predict potential risk peptides and off-targets.
keyboard_arrow_rightkeyboard_arrow_rightkeyboard_arrow_left
Alithea’s highly sensitive and reproducible HLA peptidome characterization can support the development of a variety of therapeutic options especially in the immunotherapy space.
Target discovery and validation HLA-presented peptides represent the natural target of TCR T-cell therapies and TCR-mimic antibodies. Also when developing vaccines, knowledge of which antigen-derived peptides are presented on HLA complexes can be required.
TCR T-cell therapy
TCR-mimic antibody
Vaccines
Quality control and safety Several approaches for the induction of tumor-specific T cells have been developed. If the desired peptides, but not undesired peptides are presented on a patient's HLA alleles are important quality and safety determinants. Alithea's CONZOOM technology is especially suited to answer these questions.
Immunogenicity assessment Therapeutic proteins such as antibodies, can be immunogenic in patients. This applies not only to protein therapeutics but also to CAR T constructs and any other gene therapy product that is translated to a protein.
keyboard_arrow_rightkeyboard_arrow_rightTECHNOLOGY
keyboard_arrow_left
Neozoom: revolutionizing neoantigen discovery Neoepitope-targeted therapies such as cancer vaccines and TCR-engineered T cell therapy are currently some of the most promising novel therapies.
Exact knowledge of which neoepitopes are presented by tumor cells are essential. Classical mass spectrometric strategies are limited by sensitivity or throughput and can rarely detect any neoepitopes.
Alithea’s NEOZOOM™ strategy was developed to increase sensitivity and detectability of neoepitopes and clearly outperforms classical strategies.
NEOZOOM™
Conzoom: revolutionizing targeted epitope discovery During target discovery and quality control of certain immunotherapies, it is of interest to idetify and quantify presentation of epitopes from specific genetic elements of interest.
Our CONZOOM™ technology allows to scan for gene- or construct-derived epitopes in high sensitivity and allows to optimally design follow-up experiments to profile T cell subsets by tetramers or ELISPOT assays.
CONZOOM™
Immzoom: revolutionizing immunogenicity assessment A risk in the development of therapeutic proteins is the generation of high affinity anti-drug antibodies (ADA). After treatment with therapeutic proteins (Antibody, other protein drug and even CAR T-cells), it is possible that the patients' immune system responds to the drug and neutralizes it reducing efficacy of the treatment.
By assessing HLA-presented peptides, it is possible to study these immune processes. IMMZOOM allows for highly sensitive and reproducible detection of drug-derived antigens presented on HLA class II complexes.
IMMZOOM™
IMMZOOM™
CONZOOM™
NEOZOOM™
products:
keyboard_arrow_rightkeyboard_arrow_rightkeyboard_arrow_left
Alithea Bio has laboratories located in a Biotech hotspot in central Europe close to Basel, Munich, Heidelberg at the École Supérieure Biotechnologique de Strasbourg and at the Berlin BioCube in Buch, 13125 Berlin
Contact:
Alithea Biotechnology GmbH Liebühl 2A 79104 Freiburg im Breisgau
info(@)alithea-bio.com IMPRINT - LEGAL NOTICE
keyboard_arrow_rightkeyboard_arrow_rightAbout Alithea Bio UG (haftungsbeschränkt)
keyboard_arrow_left
